Advertisement

Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant

      Abstract

      Background

      Endometrial spotting and/or bleeding (ESB) occurs in levonorgestrel subcutaneous implant (LNG SI) users. Matrix metalloproteinases (MMPs) may play a role in ESB.

      Study Design

      Women between 18 and 40 years with regular menstrual cycles had a baseline evaluation followed by LNG SI insertion and randomization to doxycycline (DOX; 20 mg) or placebo (PL) twice a day. MMP-2, MMP-9 and tissue inhibitor of MMP-1 (TIMP-1) in serum and the endometrium were estimated at baseline and at 1, 3 and 6 months after insertion.

      Results

      LNG increased serum MMP-9, while DOX decreased MMP-9 levels compared to PL after 1 month (p<.05). DOX decreased endometrial MMP-9 at 1 and 6 months compared to baseline and PL (p<.05).
      DOX increased endometrial TIMP-1 at 6 months compared with baseline and PL (p<.05). MMP-2 levels were unchanged.

      Conclusion

      LNG SI increased serum MMP-9 and TIMP-1 levels, while DOX decreased both serum and endometrial MMP-9 levels.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Abdel-Aleem H.
        • d'Arcangues C.
        • Vogelsong K.
        • Gulmezoglu A.M.
        Treatment of vaginal bleeding irregularities induced by progestin only contraceptives..
        Cochrane Database Syst Rev. 2007; : CD003449
        • Livingstone M.
        • Fraser I.S.
        Mechanisms of abnormal uterine bleeding.
        Hum Reprod Update. 2002; 8: 60-67
        • Weisberg E.
        • Hickey M.
        • Palmer D.
        • et al.
        A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon.
        Hum Reprod. 2006; 21: 295-302
        • Brache V.
        • Faundes A.
        • Alvarez F.
        Risk���benefit effects of implantable contraceptives in women.
        Expert Opin Drug Saf. 2003; 2: 321-332
        • Colli E.
        • Tong D.
        • Penhallegon R.
        • Parazzini F.
        Reasons for contraceptive discontinuation in women 20���39 years old in New Zealand.
        Contraception. 1999; 59: 227-231
        • Vekemans M.
        • Delvigne A.
        • Paesmans M.
        Continuation rates with a levonorgestrel-releasing contraceptive implant (Norplant). A prospective study in Belgium.
        Contraception. 1997; 56: 291-299
        • Diaz J.
        • Faundes A.
        • Olmos P.
        • Diaz M.
        Bleeding complaints during the first year of norplant implants use and their impact on removal rate.
        Contraception. 1996; 53: 91-95
        • Guillebaud J.
        The levonorgestrel intrauterine system: a clinical perspective from the UK.
        Ann N Y Acad Sci. 2003; 997: 185-193
        • del Carmen Cravioto M.
        • Alvarado G.
        • Canto-de-Cetina T.
        • et al.
        A multicenter comparative study on the efficacy, safety, and acceptability of the contraceptive subdermal implants Norplant and Norplant-II.
        Contraception. 1997; 55: 359-367
        • Riphagen F.E.
        Intrauterine application of progestins in hormone replacement therapy: a review.
        Climacteric. 2000; 3: 199-211
        • Shoupe D.
        • Mishell Jr., D.R.
        • Bopp B.L.
        • Fielding M.
        The significance of bleeding patterns in Norplant implant users.
        Obstet Gynecol. 1991; 77: 256-260
        • Fraser I.S.
        • Hickey M.
        Endometrial vascular changes and bleeding disturbances with long-acting progestins.
        Steroids. 2000; 65: 665-670
        • Hickey M.
        • d'Arcangues C.
        Mechanisms underlying menstrual bleeding disturbances with progestogens.
        Ernst Schering Res Found Workshop. 2005; 52: 191-217
        • Marsh M.M.
        • Butt A.R.
        • Riley S.C.
        • et al.
        Immunolocalization of endothelin and neutral endopeptidase in the endometrium of users of subdermally implanted levonorgestrel (Norplant).
        Hum Reprod. 1995; 10: 2584-2589
        • Goodger A.M.
        • Rogers P.A.
        • Affandi B.
        Endometrial endothelial cell proliferation in long-term users of subdermal levonorgestrel.
        Hum Reprod. 1994; 9: 1647-1651
        • Hickey M.
        • Fraser I.
        • Dwarte D.
        • Graham S.
        Endometrial vasculature in Norplant users: preliminary results from a hysteroscopic study.
        Hum Reprod. 1996; 11: 35-44
        • Hickey M.
        • Dwarte D.
        • Fraser I.S.
        Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding.
        Hum Reprod. 2000; 15: 1509-1514
        • Vincent A.J.
        • Zhang J.
        • Ostor A.
        • et al.
        Matrix metalloproteinase-1 and -3 and mast cells are present in the endometrium of women using progestin-only contraceptives.
        Hum Reprod. 2000; 15: 123-130
        • Vincent A.J.
        • Malakooti N.
        • Zhang J.
        • Rogers P.A.
        • Affandi B.
        • Salamonsen L.A.
        Endometrial breakdown in women using Norplant is associated with migratory cells expressing matrix metalloproteinase-9 (gelatinase B).
        Hum Reprod. 1999; 14: 807-815
        • Hampton A.L.
        • Nie G.
        • Salamonsen L.A.
        Progesterone analogues similarly modulate endometrial matrix metalloproteinase-1 and matrix metalloproteinase-3 and their inhibitor in a model for long-term contraceptive effects.
        Mol Hum Reprod. 1999; 5: 365-371
        • Birkedal-Hansen H.
        • Moore W.G.
        • Bodden M.K.
        • et al.
        Matrix metalloproteinases: a review.
        Crit Rev Oral Biol Med. 1993; 4: 197-250
        • Salamonsen L.A.
        • Woolley D.E.
        Matrix metalloproteinases in normal menstruation.
        Hum Reprod. 1996; 11: 124-133
        • Salamonsen L.A.
        • Woolley D.E.
        Menstruation: induction by matrix metalloproteinases and inflammatory cells.
        J Reprod Immunol. 1999; 44: 1-27
        • Singer C.F.
        • Marbaix E.
        • Lemoine P.
        • Courtoy P.J.
        • Eeckhout Y.
        Local cytokines induce differential expression of matrix metalloproteinases but not their tissue inhibitors in human endometrial fibroblasts.
        Eur J Biochem. 1999; 259: 40-45
        • Chegini N.
        • Rhoton-Vlasak A.
        • Williams R.S.
        Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding.
        Fertil Steril. 2003; 80: 564-570
        • Di Nezza L.A.
        • Jobling T.
        • Salamonsen L.A.
        Progestin suppresses matrix metalloproteinase production in endometrial cancer.
        Gynecol Oncol. 2003; 89: 325-333
        • Kaitu'u T.J.
        • Shen J.
        • Zhang J.
        • Morison N.B.
        • Salamonsen L.A.
        Matrix metalloproteinases in endometrial breakdown and repair: functional significance in a mouse model.
        Biol Reprod. 2005; 73: 672-680
        • Li R.
        • Luo X.
        • Archer D.F.
        • Chegini N.
        Doxycycline alters the expression of matrix metalloproteases in the endometrial cells exposed to ovarian steroids and pro-inflammatory cytokine.
        J Reprod Immunol. 2007; 73: 118-129
        • Borkakoti N.
        Matrix metalloproteases: variations on a theme.
        Prog Biophys Mol Biol. 1998; 70: 73-94
        • Rogers P.A.
        • Au C.L.
        • Affandi B.
        Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel.
        Hum Reprod. 1993; 8: 1396-1404
        • Hiscock N.
        • Chan M.H.
        • Bisucci T.
        • Darby I.A.
        • Febbraio M.A.
        Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity.
        FASEB J. 2004; 18: 992-994
        • Maximova O.A.
        • Taffs R.E.
        • Pomeroy K.L.
        • Piccardo P.
        • Asher D.M.
        Computerized morphometric analysis of pathological prion protein deposition in scrapie-infected hamster brain.
        J Histochem Cytochem. 2006; 54: 97-107
        • Brey E.M.
        • Lalani Z.
        • Johnston C.
        • et al.
        Automated selection of DAB-labeled tissue for immunohistochemical quantification.
        J Histochem Cytochem. 2003; 51: 575-584
        • Aasmundstad T.A.
        • Haugen O.A.
        • Johannesen E.
        • Hoe A.L.
        • Kvinnsland S.
        Oestrogen receptor analysis: correlation between enzyme immunoassay and immunohistochemical methods.
        J Clin Pathol. 1992; 45: 125-129
        • Lehr H.A.
        • Mankoff D.A.
        • Corwin D.
        • Santeusanio G.
        • Gown A.M.
        Application of Photoshop-based image analysis to quantification of hormone receptor expression in breast cancer.
        J Histochem Cytochem. 1997; 45: 1559-1565
        • Lehr H.A.
        • Jacobs T.W.
        • Yaziji H.
        • Schnitt S.J.
        • Gown A.M.
        Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis.
        Am J Clin Pathol. 2001; 115: 814-822
        • Meckstroth K.R.
        • Darney P.D.
        Implantable contraception.
        Obstet Gynecol Clin North Am. 2000; 27: 781-815
        • Kovalevsky G.
        • Barnhart K.
        Norplant and other implantable contraceptives.
        Clin Obstet Gynecol. 2001; 44: 92-100
        • Galant C.
        • Vekemans M.
        • Lemoine P.
        • et al.
        Temporal and spatial association of matrix metalloproteinases with focal endometrial breakdown and bleeding upon progestin-only contraception.
        J Clin Endocrinol Metab. 2000; 85: 4827-4834
        • Bischof P.
        • Meisser A.
        • Campana A.
        • Tseng L.
        Effects of decidua-conditioned medium and insulin-like growth factor binding protein-1 on trophoblastic matrix metalloproteinases and their inhibitors.
        Placenta. 1998; 19: 457-464
        • Labied S.
        • Galant C.
        • Nisolle M.
        • et al.
        Differential elevation of matrix metalloproteinase expression in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time.
        Hum Reprod. 2009; 24: 113-121
        • Malik S.
        • Day K.
        • Perrault I.
        • Charnock-Jones D.S.
        • Smith S.K.
        Reduced levels of VEGF-A and MMP-2 and MMP-9 activity and increased TNF-alpha in menstrual endometrium and effluent in women with menorrhagia.
        Hum Reprod. 2006; 21: 2158-2166
        • Marbaix E.
        • Kokorine I.
        • Henriet P.
        • Donnez J.
        • Courtoy P.J.
        • Eeckhout Y.
        The expression of interstitial collagenase in human endometrium is controlled by progesterone and by oestradiol and is related to menstruation.
        Biochem J. 1995; 305: 1027-1030
        • Skinner J.L.
        • Riley S.C.
        • Gebbie A.E.
        • Glasier A.F.
        • Critchley H.O.
        Regulation of matrix metalloproteinase-9 in endometrium during the menstrual cycle and following administration of intrauterine levonorgestrel.
        Hum Reprod. 1999; 14: 793-799
        • Vincent A.J.
        • Zhang J.
        • Ostor A.
        • et al.
        Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: a role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding?.
        Hum Reprod. 2002; 17: 1189-1198
        • Golub L.M.
        • Sorsa T.
        • Lee H.M.
        • et al.
        Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva.
        J Clin Periodontol. 1995; 22: 100-109
        • Greenwald R.A.
        Treatment of destructive arthritic disorders with MMP inhibitors. Potential role of tetracyclines.
        Ann N Y Acad Sci. 1994; 732: 181-198
        • Murphy G.
        • Stanton H.
        • Cowell S.
        • et al.
        Mechanisms for pro matrix metalloproteinase activation.
        Apmis. 1999; 107: 38-44
        • Jiang Y.
        • Goldberg I.D.
        • Shi Y.E.
        Complex roles of tissue inhibitors of metalloproteinases in cancer.
        Oncogene. 2002; 21: 2245-2252
        • Galant C.
        • Berliere M.
        • Dubois D.
        • et al.
        Focal expression and final activity of matrix metalloproteinases may explain irregular dysfunctional endometrial bleeding.
        Am J Pathol. 2004; 165: 83-94
        • Corcoran M.L.
        • Hewitt R.E.
        • Kleiner Jr., D.E.
        • Stetler-Stevenson W.G.
        MMP-2: expression, activation and inhibition.
        Enzyme Protein. 1996; 49: 7-19
        • Hu J.
        • Zhang X.
        • Nothnick W.B.
        • Spencer T.E.
        Matrix metalloproteinases and their tissue inhibitors in the developing neonatal mouse uterus.
        Biol Reprod. 2004; 71: 1598-1604
        • Petrinec D.
        • Liao S.
        • Holmes D.R.
        • Reilly J.M.
        • Parks W.C.
        • Thompson R.W.
        Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase.
        J��Vasc Surg. 1996; 23: 336-346
        • Vincent A.J.
        • Salamonsen L.A.
        The role of matrix metalloproteinases and leukocytes in abnormal uterine bleeding associated with progestin-only contraceptives.
        Hum Reprod. 2000; 15: 135-143